NBIX

#615
Neurocrine Biosciences, Inc. - Common Stock
158.3 0 USD
+1.22%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
158.30
158.30
Yıllık Aralık
1.55
162.39
Günlük Değişim
+1.22%
Aylık Değişim
+22.00%
6 Aylık Değişim
+4.04%
Yıllık Değişim
+9.17%
Önceki Kapanış
156.3 9
Open
158.3 0
Düşük
158.3 0
High
158.3 0
Hacim
309
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler
Çeyreklik Yıllık
  • Market Capitalization 15.92 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry İlaç Üreticileri - Özel ve Eşdeğer
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
30.37
Fiyat/satışlar oranı
5.08

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Haberler